Jazz Pharmaceuticals plc (JAZZ)
Automate Your Wheel Strategy on JAZZ
With Tiblio's Option Bot, you can configure your own wheel strategy including JAZZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JAZZ
- Rev/Share 66.6591
- Book/Share 68.4644
- PB 1.5703
- Debt/Equity 1.2982
- CurrentRatio 3.3762
- ROIC 0.0766
- MktCap 6505537610.0
- FreeCF/Share 24.4087
- PFCF 4.3708
- PE 13.5958
- Debt/Assets 0.4699
- DivYield 0
- ROE 0.119
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JAZZ | UBS | Neutral | Buy | $145 | $179 | March 7, 2025 |
| Downgrade | JAZZ | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Feb. 26, 2025 |
| Upgrade | JAZZ | Wells Fargo | Equal Weight | Overweight | $130 | $170 | Feb. 13, 2025 |
| Upgrade | JAZZ | Morgan Stanley | Equal Weight | Overweight | $140 | $175 | Dec. 12, 2024 |
News
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Read More
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profile Findings presented today at ASCO 2025 and concurrently published in The Lancet Oncology For U.S. media and investors only DUBLIN , June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2 trial evaluating Ziihera® (zanidatamab-hrii), a dual HER2-targeted bispecific antibody, in combination with chemotherapy for the investigational use in first-line HER2-positive (IHC 3+ or IHC …
Read More
Jazz Pharmaceuticals: One Step Forward, One Back
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Jazz took a step forward with the Chimerix acquisition that should further diversify its revenue base. The oxybate business experienced a setback when Avadel won the appeal that allows Lumryz to compete with Jazz's Xywav in idiopathic hypersomnia. There are three potential catalysts for the oncology business in the second half of the year that should translate to a revenue growth inflection point in 2026.
Read More
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
Read More
Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Jeff Macdonald - Executive Director, Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renee Gala - President and Chief Operating Officer Rob Iannone - Executive Vice President, Global Head of R&D and Chief Medical Officer Phil Johnson - Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Jessica Fye - JP Morgan David Amsellem - Piper Sandler Marc Goodman - Leerink Partners. Annabel Samimy - Stifle Joseph Thome - TD Cowen Gregory Renza - RBC Capital Markets …
Read More
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $1.68 per share, missing the Zacks Consensus Estimate of $4.51 per share. This compares to earnings of $2.68 per share a year ago.
Read More
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
Read More
3 Unconventional Cannabis Stocks to Watch in 2025
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
Read More
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
Published: April 25, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , April 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+)† biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.1 "This positive CHMP opinion is a welcome step for physicians and patients in Europe who …
Read More
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
Read More
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Jazz (JAZZ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
5 High ROE Stocks to Buy as Markets Face Tariff Bloodbath
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
ANET, GLW, JAZZ, AES and PPC are some of the stocks with high ROE to profit from as markets recoiled on tariff war.
Read More
JAZZ or ARGX: Which Is the Better Value Stock Right Now?
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
4 Top PEG Stocks Based on GARP Approach to Smart Investing
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Here are four discounted PEG stocks, JAZZ, FMS, DAN and ITRI, which qualify our screening criteria.
Read More
Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 38.9% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
JAZZ or ILMN: Which Is the Better Value Stock Right Now?
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Read More
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
4 Discounted PEG Stocks Offering the Best Returns to Value Investors
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Here we present four discounted PEG stocks that qualify our screening criteria, TAP, BMRN, DVN and JAZZ.
Read More
Beat Market Volatility With 4 Low-Beta Stocks: PGR, PSO, TXO & JAZZ
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. PGR, PSO, TXO & JAZZ are well-poised to gain.
Read More
Wall Street Analysts See a 29.63% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 29.6% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Best Momentum Stocks to Buy for March 3rd
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
STRL. BATRA and JAZZ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 3, 2025.
Read More
4 Stocks Trading Near 52-Week High With More Upside Potential
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Stocks like NFG, ENS, TAP and JAZZ are seeing price strength and have a high chance of carrying the momentum forward.
Read More
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy?
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates, and the 2025 revenue outlook is slightly below consensus. The delay in zanidatamab's phase 3 trial results is slightly disappointing but could indicate a better-than-expected treatment effect. I continue to see Jazz as a valuation re-rating candidate, driven by zanidatamab and Zepzelca, return to growth and reduced perceptions of the risks for the oxybate franchise.
Read More
About Jazz Pharmaceuticals plc (JAZZ)
- IPO Date 2007-06-01
- Website https://www.jazzpharma.com
- Industry Biotechnology
- CEO Bruce C. Cozadd
- Employees 2800